⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
prnewswire.com
ABBV
ALTO
NRXP
VNDA
Form 8-K
sec.gov
VNDA
Crafting Announces General Availability of Crafting for Agents and $5.5M Seed Round to Build Infrastructure for AI-Driven Engineering
globenewswire.com
VNDA
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
ANAB
VNDA
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
prnewswire.com
VNDA
ANAB
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
prnewswire.com
VNDA
Form 8-K
sec.gov
VNDA